Zipalertinib, 99.62%
cas: 1661854-97-2 — see every product listed under this CAS number, including other names
Zipalertinib, 99.62% (CAS 1661854-97-2) is a chemical reagent available from Chemat. Available pack sizes: 5 mg, 1 mg, 50 mg, 10 mg, 25 mg, 10mM/1mL, 100 mg. Offered by: MedChemExpress.
| brand | MedChemExpress |
|---|---|
| catalog number | HY-112299-5 mg |
| cas | 1661854-97-2 |
| size | 5 mg |
| availability | In stock |
Need more information?
Ask us about this product — we're happy to help.
Available pack sizes
| brand | size | price | |
|---|---|---|---|
| MedChemExpress | 5 mg | 1318.15 Pln | |
| MedChemExpress | 1 mg | 649.42 Pln | |
| MedChemExpress | 50 mg | 5349.14 Pln | |
| MedChemExpress | 10 mg | 2037.97 Pln | |
| MedChemExpress | 25 mg | 3955.94 Pln | |
| MedChemExpress | 10mM/1mL | 1438.90 Pln | |
| MedChemExpress | 100 mg | 7174.24 Pln |
properties
| delivery time | 1-2 weeks |
|---|---|
| purity | 99.62% |
Zipalertinib is a member of the class of acrylamides that is (8S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine in which the amino group at position 8S is substituted by an acryloyl group. It a covalent epidermal growth factor receptor inhibitor that targets exon 20 insertion mutations. It has a role as an antineoplastic agent, an apoptosis inducer and an epidermal growth factor receptor antagonist. It is a secondary carboxamide, a member of acrylamides, a member of quinolines, an organic heterotricyclic compound, an aromatic amine and a primary amino compound.
Source: ChEBI
| Molecular formula | C23H20N6O |
|---|---|
| Molecular weight | 396.4 g/mol |
| IUPAC name | N-[(8S)-4-amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide |
| InChIKey | MKCYPWYURWOKST-INIZCTEOSA-N |
| SMILES | CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C |
Computed by PubChem (NCBI)
Synonyms:
Zipalertinib, Cln 081, Pan-EGFR Inhibitor CLN-081, Mutation-specific EGFR TKI TAS6417, EGFR Mutant-specific Inhibitor CLN-081, Pan-mutation-selective EGFR Inhibitor CLN-081, Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081, Zipalertinib [INN], zipalertinibum, Zipalertinib [WHO-DD]